A Phase 1, Open Label, Dose Escalation Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Subjects With Relapsed or Refractory Solid Tumors.

Trial Profile

A Phase 1, Open Label, Dose Escalation Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Subjects With Relapsed or Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs BIIB 022 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jan 2011 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
    • 03 Feb 2010 Planned end date changed from 1 May 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top